Effectiveness of a modified doxorubicin-etoposide-methylprednisolone regimen for the treatment of refractory or relapsed macrophage activation syndrome in adults
单位：[1]Department of Hematology, Beijing Friendship Hospital, Capital Medical University, Beijing, China临床科室血液科血液科首都医科大学附属北京友谊医院[2]Department of General Practice, Beijing Friendship Hospital, Capital Medical University, Beijing, China临床科室全科医学科全科医学科首都医科大学附属北京友谊医院
第一作者单位：[1]Department of Hematology, Beijing Friendship Hospital, Capital Medical University, Beijing, China
通讯作者：
通讯机构：[1]Department of Hematology, Beijing Friendship Hospital, Capital Medical University, Beijing, China[2]Department of General Practice, Beijing Friendship Hospital, Capital Medical University, Beijing, China[*1]Department of Hematology, Department of General Practice, Beijing Friendship Hospital, Capital Medical University, Yongan Road, Xicheng District, 100050 Beijing, China,
推荐引用方式(GB/T 7714)：
He Lingbo,Jin Zhili,Liu Menghan,et al.Effectiveness of a modified doxorubicin-etoposide-methylprednisolone regimen for the treatment of refractory or relapsed macrophage activation syndrome in adults[J].POLISH ARCHIVES of INTERNAL MEDICINE-POLSKIE ARCHIWUM MEDYCYNY WEWNETRZNEJ.2022,132(3):doi:10.20452/pamw.16226.
APA：
He Lingbo,Jin Zhili,Liu Menghan,Zhang Ruoxi,Wang Zhao&Wang Yini.(2022).Effectiveness of a modified doxorubicin-etoposide-methylprednisolone regimen for the treatment of refractory or relapsed macrophage activation syndrome in adults.POLISH ARCHIVES of INTERNAL MEDICINE-POLSKIE ARCHIWUM MEDYCYNY WEWNETRZNEJ,132,(3)
MLA：
He Lingbo,et al."Effectiveness of a modified doxorubicin-etoposide-methylprednisolone regimen for the treatment of refractory or relapsed macrophage activation syndrome in adults".POLISH ARCHIVES of INTERNAL MEDICINE-POLSKIE ARCHIWUM MEDYCYNY WEWNETRZNEJ 132..3(2022)
